Wuxi Biologics ADR Reports FY Results

Seeking AlphaMar 27 07:41 ET

Daiwa Capital Markets: Raised WUXI BIO (02269) Target Price to HKD 35, rating "Buy".

The group stated that, due to a significant increase in new projects, the revenue scale of Phase III and commercialization projects continues to expand, therefore the target is to achieve a revenue growth of 12% to 15% this year, with an acceleration in growth starting next year.

Zhitong FinanceMar 27 04:44 ET

Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?

① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.

cls.cnMar 27 04:08 ET

Trending Industry Today: WUXI BIO Leads Gains In CRO Stocks

Moomoo NewsMar 27 02:40 ET

Trending Industry Today: WUXI XDC Leads Gains In Biotechnology Stocks

Moomoo NewsMar 27 02:20 ET

[Brokerage Focus] BOCOM INTL maintains a neutral rating on WUXI BIO (02269) and indicates that the marginal improvement of the three main Business segments is highly certain.

Jinwu Financial News | BOCOM INTL's research report indicates that WUXI BIO (02269) shows a clear recovery trend in 2H24. After excluding the impact of COVID-19 projects, revenue increased by 13.1%, with a growth of 18.2% in 2H24, significantly recovering from the 7.7% in 1H24. Additionally, after excluding WUXI XDC, the annual revenue still sees an 8% increase. As of the end of 2024, the backlog of unfulfilled orders reached 18.5 billion dollars, a year-on-year decrease of 10%, primarily due to the termination of the Merck vaccine project, but after excluding this impact, there was a 5% increase. The firm indicated that the company's RDM business is developing simultaneously, with continuous improvement in growth rates starting from 2025: management guidance:

Jingu Financial NewsMar 26 22:05 ET